[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100650210":3},{"organization":4,"armGroups":7,"interventions":25,"overallOfficials":36,"centralContacts":41,"locations":10,"responsibleParty":47,"collaborators":10,"id":49,"slug":50,"hasResults":51,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":10,"eligibilityCriteria":55,"healthyVolunteers":56,"sex":57,"minAge":58,"maxAge":10,"enrollmentInfo":59,"targetDuration":10,"studyType":62,"phases":10,"briefSummary":63,"conditions":64,"keywords":68,"overallStatus":73,"whyStopped":10,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":10},{"fullName":5,"class":6},"CanSino Biologics Inc.","INDUSTRY",[8,13,17,21],{"label":9,"type":10,"description":10,"interventionNames":11},"Previously received the Tdcp vaccine at age 18 and older",null,[12],"Other: Previously received the Tdcp vaccine at age 18 and older",{"label":14,"type":10,"description":10,"interventionNames":15},"Previously received the Tdcp vaccine at age 12-17",[16],"Other: Previously received the Tdcp vaccine at age 12-17",{"label":18,"type":10,"description":10,"interventionNames":19},"Previously received the Tdcp vaccine at age 6-11",[20],"Other: Previously received the Tdcp vaccine at age 6-11",{"label":22,"type":10,"description":10,"interventionNames":23},"Previously received the DT vaccine at age 6-11",[24],"Other: Previously received the DT vaccine at age 6-11",[26,30,32,34],{"type":27,"name":9,"description":28,"armGroupLabels":29,"otherNames":10},"OTHER","Approximately 3-4 mL of venous blood will be collected 2.5 years, 5 years, and 10 years after vaccination for a study on immune persistence.",[9],{"type":27,"name":14,"description":28,"armGroupLabels":31,"otherNames":10},[14],{"type":27,"name":18,"description":28,"armGroupLabels":33,"otherNames":10},[18],{"type":27,"name":22,"description":28,"armGroupLabels":35,"otherNames":10},[22],[37],{"name":38,"affiliation":39,"role":40},"Xiaoyu Liu","Center for Disease Prevention and Control, Shaanxi Province","PRINCIPAL_INVESTIGATOR",[42],{"name":43,"role":44,"phone":45,"phoneExt":10,"email":46},"Ying Wang","CONTACT","022-58213600-6051","ying.wang@cansinotech.com",{"type":48,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100650210","a-clinical-study-on-immunogenicity-persistence-of-adsorbed-5-component-acellular-pertussis-diphtheria-and-tetanus-combined-vaccine-100650210",false,"NCT07744347","A Clinical Study on Immunogenicity Persistence of Adsorbed 5-component Acellular Pertussis, Diphtheria and Tetanus Combined Vaccine","Phase I Clinical Study on Immunogenicity Persistence of Adsorbed 5-component Acellular Pertussis, Diphtheria and Tetanus Combined Vaccine","Inclusion Criteria:\n\n* Participants in the 6-11-year-old, 12-17-year-old, and ≥18-year-old groups from the Phase I clinical trial of the adsorbed acellular pentavalent (five-component) DTP-polio combined vaccine (for individuals aged 6 and older) (Protocol No.: CTP-Tdcp-001) who were included in the protocol-defined analysis set;\n* Willingness to provide identification documents;\n* Informed consent must be obtained from the trial participant and\u002For guardian and\u002For authorized representative, and the informed consent form must be signed;\n* The trial participant and\u002For guardian and\u002For authorized representative must be able and willing to comply with the requirements of the clinical study protocol and be able to complete the full course of study follow-up.\n\nExclusion Criteria:\n\n* Received another DTP-type vaccine after completing the CTP-Tdcp-001 study;\n* Developed a DTP-related illness since the completion of the CTP-Tdcp-001 study;\n* Has a coagulation disorder;\n* In the investigator's judgment, the participant has any other factors that make them unsuitable for participation in the clinical trial.",true,"ALL","6 Years",{"count":60,"type":61},160,"ESTIMATED","OBSERVATIONAL","This clinical trial will enroll 160 participants who previously took part in the Phase I clinical trial of the adsorbed acellular pentavalent (five-component) DTP-polio combination vaccine (for individuals aged 6 years and older) (Protocol No.: CTP-Tdcp-001). Approximately 3-4 mL of venous blood will be collected from each participant 2.5 years, 5 years, and 10 years after vaccination for a study on immune persistence.",[65,66,67],"Diphtheria","Tetanus","Pertussis",[69,70,71,72],"Vaccine","Five Components","≥6 years","Immune Persistence","NOT_YET_RECRUITING","2026-07-30",{"date":76,"type":77},"2026-08-04","ACTUAL",{"date":79,"type":61},"2026-10-15",{"date":81,"type":61},"2033-10-15",{"name":5,"class":6}]